Expression of Estrogen Receptors α and β in Early Steps of Human Breast Carcinogenesis

  • Pascal Roger
  • Majida Esslimani-Sahla
  • Christophe Delfour
  • Gwendal Lazennec
  • Henri Rochefort
  • Thierry Maudelonde
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 617)

Association of hormonal factors and preinvasive mammary lesions increase the risk of sporadic breast cancer (BC) incidence. Indeed, the mitogenic activity of estrogens and their role as a promoter of BC was confirmed by epidemiological, clinical, and experimental studies (1). Preinvasive mammary lesions frequently precede the development of invasive BC. They correspond to nonproliferative and proliferative benign breast disease without or with atypia and ductal carcinoma in-situ (DCIS) (2).


Breast Cancer Sporadic Breast Cancer Mammary Carcinogenesis Normal Gland Mammary Lesion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    The Endogenous Hormones and Breast Cancer Collaborative Group (2002) Endogenous sex hormones and breast cancer in postmenopausal women: reanalysis of nine prospective studies. J Natl Cancer Inst 94:606–16.Google Scholar
  2. 2.
    Tavassoli FA, Devilee P (2003) World Health Organization Classification of Tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press.Google Scholar
  3. 3.
    Vogelstein B, Kinzler KW (1993) The multistep nature of cancer. Trends Genet 9:138–41.PubMedCrossRefGoogle Scholar
  4. 4.
    Dupont WD, Page DL (1985) Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–51.PubMedGoogle Scholar
  5. 5.
    Hartmann LC, Sellers TA, Frost MH, et al. (2005) Benign breast disease and the risk of breast cancer. N Engl J Med 353(3):229–37.PubMedCrossRefGoogle Scholar
  6. 6.
    Fisher B, Costantino JP, Wickerham DL, et al. (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 16;90(18):1371–88.CrossRefGoogle Scholar
  7. 7.
    Martino S, Cauley JA, Barrett-Connor E, et al. (2004) Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst 1;96(23):1751–61.Google Scholar
  8. 8.
    Vogel VG, Costantino JP, Wickerham DL el al. (2006) Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 21;295(23):2727–41.CrossRefGoogle Scholar
  9. 9.
    Enmark E, Pelto-Huikko M, Grandien K, et al. (1997) Human estrogen receptor ß-gene structure, chromosomal localization, and expression pattern. J Clin Endocrinol Metab 82:4258–65.PubMedCrossRefGoogle Scholar
  10. 10.
    Ogawa S, Inoue S, Watanabe T et al. (1998) Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26:3505–12.PubMedCrossRefGoogle Scholar
  11. 11.
    Leyghe E, Dotzlaw H, Waton PH, et al. (1998) Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 1;58(15):3197–201.Google Scholar
  12. 12.
    Pujol P, Rey JM, Nirde P, et al. (1998) Differential expression of estrogen receptor alpha and beta as a potential marker of ovarian carcinogenesis. Cancer Res 58:5367–73.PubMedGoogle Scholar
  13. 13.
    Esslimani-Sahla M, Simony-Lafontaine J, Kramar A, et al. (2004) ERß level helps to predict Tam resistance in breast cancer but not its ERßcx variant. Clin Cancer Res 10:5769–76.PubMedCrossRefGoogle Scholar
  14. 14.
    Skliris GP, Leygue E, Curtis–Snell L, et al. (2006) Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer 95(5):616–26.PubMedCrossRefGoogle Scholar
  15. 15.
    Sorlie T, Perou CM, Tibshirani R, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98(19):10869–74.PubMedCrossRefGoogle Scholar
  16. 16.
    Leygue E, Dotzlaw H, Watson PH, et al. (1999) Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue. Cancer Res 15;59(6):1175–9.Google Scholar
  17. 17.
    Rochefort H, Cavailles V, Augereau P, et al. (1989) Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer. J Steroid Biochem 34(1–6):177–82.PubMedCrossRefGoogle Scholar
  18. 18.
    Spyratos F, Maudelonde T, Brouillet JP, et al. (1989) An independent prognostic factor for metastasis of breast cancer. Lancet ii:1115–18.CrossRefGoogle Scholar
  19. 19.
    Khan SA, Rogers MA, Khurana KK, et al. (1998) Estrogen receptor expression in benign breast epithelium and breast cancer risk. J Natl Cancer Inst 90:37–42.PubMedCrossRefGoogle Scholar
  20. 20.
    Roger P, Esslimani Sahla M, Makela S, et al. (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61:2537–2541.PubMedGoogle Scholar
  21. 21.
    Shaaban AM, Jarvis C, Moore F, et al. (2005) Prognostic significance of estrogen receptor Beta in epithelial hyperplasia of usual type with known outcome. Am J Surg Pathol 29(12):1593–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Esslimani Sahla M, Kramar A, Simony-Lafontaine J, et al. (2005) Increased estrogen receptor beta cx expression during mammary carcinogenesis. Clin Cancer Res 11:3170–74.PubMedCrossRefGoogle Scholar
  23. 23.
    Matthews J, Gustafsson JA (2003) Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol Interv 3(5):281–92. Review.PubMedCrossRefGoogle Scholar
  24. 24.
    Lazennec G, Bresson D, Lucas A, et al. (2001) ERß inhibits proliferation and invasion of breast cancer cells. Endocrinology 142:4120–30.PubMedCrossRefGoogle Scholar
  25. 25.
    Zhao C, Lam EW-F, Sunters A, et al. (2003) Expression of estrogen receptor ß isoforms in normal breast epithelial cells and human breast cancer: regulation by methylation. Oncogene 22:7600–6.PubMedCrossRefGoogle Scholar
  26. 26.
    Rochefort H, Garcia M, Glondu M, et al. (2000) Cathepsin D in breast cancer: Mechanisms and clinical applications. A 1999 overview. Clin Chim Acta 291(2):157–70.PubMedCrossRefGoogle Scholar
  27. 27.
    Maudelonde T, Khalaf S, Garcia M, et al. (1988) Immunoenzymatic assay of Mr 52, OOO cathepsin D in 182 breast cancer cytosols. Low correlation with other prognostic parameters. Cancer Res 48:462–6.PubMedGoogle Scholar
  28. 28.
    Roger P, Daures JP, Maudelonde T, et al. (2000) Dissociated overexpression of cathepsin-D and estrogen receptor alpha in preinvasive mammary tumors. Hum Pathol 31(5):593–600.PubMedCrossRefGoogle Scholar
  29. 29.
    Shaaban AM, O’Neill PA, Davies MP, et al. (2003) Declining estrogen receptor-beta expression defines malignant progression of human breast neoplasia. Am J Surg Pathol 27(12):1502–12.PubMedCrossRefGoogle Scholar
  30. 30.
    Simpson PT, Reis-Filho JS, Gale T, et al. (2005) Molecular evolution of breast cancer. J Pathol 205(2):248–54. Review.PubMedCrossRefGoogle Scholar
  31. 31.
    Brouillet JP, Dujardin MA, Chalbos D, et al. (2001) Analysis of the potential contribution of estrogen receptor (ER) α in ER cytosolic assay of breast cancer. Int J Cancer 95:205–8.PubMedCrossRefGoogle Scholar
  32. 32.
    Clarke Rb, Howell A, Potten CS, et al. (1997) Dissociation between steroid receptor expression and cell proliferation in the human breast. Cancer Res 15;57(22):4987–91.Google Scholar
  33. 33.
    Rochefort H, Capony F, Garcia M, et al. (1987) Estrogen-induced lysosomal proteases secreted by breast cancer cells. A role in carcinogenesis? J Steroid Biochem 34:177–82.CrossRefGoogle Scholar

Copyright information

© Springer 2008

Authors and Affiliations

  • Pascal Roger
    • 1
  • Majida Esslimani-Sahla
    • 2
  • Christophe Delfour
  • Gwendal Lazennec
    • 3
  • Henri Rochefort
    • 4
  • Thierry Maudelonde
    • 5
  1. 1.Lab. D’Anatomie et Cytologie PatholHospital LapeyronieMontpellierFrance
  2. 2.Department of PathologieCRLC Val D’Aurelle ParcEuromedecineMontpellierFrance
  3. 3.Inserm Unit 540MontpellierFrance
  4. 4.Montpellier University and INSERM Unit 540 Hormone and Cancer UnitMontpellierFrance
  5. 5.Department of Cell BiologyUniversity of Montpellier 1-INSERM Unit 540 Hospital Arnaud de VilleneuveMontpellierFrance

Personalised recommendations